Welcome to our dedicated page for nwrn news (Ticker: nwrn), a resource for investors and traders seeking the latest updates and insights on nwrn stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect nwrn's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of nwrn's position in the market.
Newron Pharmaceuticals (SIX: NWRN) reported its financial results for 2020, highlighting a net loss of EUR 21.0 million, slightly higher than EUR 20.2 million in 2019. Despite the challenges posed by the COVID-19 pandemic, Newron completed enrollment for its evenamide study in schizophrenia, with results expected by March 2021. The company plans to initiate its Phase III program for evenamide in Q3 2021. Cash reserves stood at EUR 31.3 million at year-end, down from EUR 39.2 million at the beginning of 2020. Xadago royalty income rose 10% to EUR 5.2 million.
